BTG swoops on Biocompatibles

Click to follow
The Independent Online

BTG unveiled plans to expand in the growing market for cancer drugs yesterday, agreeing to buy its smaller pharmaceuticals rival Biocompatibles in a £156m cash and shares deal.

The news triggered a sharp decline in BTG's shares, which fell almost 8 per cent to 231.6p on fears that it might be overpaying, with some analysts suggesting that a price of more than four times Biocompatibles' 2010 earnings was "expensive".

BTG, which acquired the biotech firm Protherics in a £218m deal two years ago, has been on the lookout for high-growth and high-margin products to expand its portfolio. It said Biocompatibles, which targets treatments to a specific parts of the body, and specialises in tackling liver cancer, fitted its portfolio neatly.